BAN 2401

Drug Profile

BAN 2401

Alternative Names: BAN-2401

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator BioArctic Neuroscience
  • Developer Eisai Co Ltd
  • Class Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 01 May 2015 Eisai completes a phase I trial in Alzheimer's disease in Japan (NCT02094729)
  • 09 May 2014 Eisai expands collaboration with Biogen Idec to develop and commercialise BAN 2401 and E 2609 to include Japan
  • 05 Mar 2014 Eisai and Biogen Idec enter into a collaboration to develop and commercialise Eisai's drug candidates, BAN 2401 and E 2609, for the treatment of Alzheimer's disease in the US and EU
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top